MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; and a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs. The company was founded in 1992 and is headquartered in Planegg, Germany.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+49-89-899270
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$87.19 million
Profitability
Miscellaneous
Employees329
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable
MorphoSys (ETR:MOR) Frequently Asked Questions
What is MorphoSys' stock symbol?
MorphoSys trades on the ETR under the ticker symbol "MOR."
When is MorphoSys' next earnings date?
What price target have analysts set for MOR?
9 equities research analysts have issued 1 year target prices for MorphoSys' shares. Their forecasts range from €56.00 to €125.00. On average, they expect MorphoSys' share price to reach €100.78 in the next twelve months. This suggests a possible upside of 8.0% from the stock's current price. View Analyst Price Targets for MorphoSys.
What is the consensus analysts' recommendation for MorphoSys?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MorphoSys.
Has MorphoSys been receiving favorable news coverage?
Media headlines about MOR stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. MorphoSys earned a news impact score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of MorphoSys' key competitors?
Some companies that are related to MorphoSys include Moderna Inc (NASDAQ) (MRNA), Cronos Group (CRON), BTG (BTG), Abcam (ABC), Genus (GNS), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), ProMetic Life Sciences (PLI), Mesoblast (MSB), Polynovo (PNV), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Biotest (BIO), Starpharma (SPL) and Oxford BioMedica (OXB).
What other stocks do shareholders of MorphoSys own?
Who are MorphoSys' key executives?
MorphoSys' management team includes the folowing people:
- Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 59)
- Mr. Jens H. Holstein, CFO & Member of Management Board (Age 55)
- Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 49)
- Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 57)
- Mr. Klaus De Wall, Head of Accounting & Tax
What is MorphoSys' stock price today?
One share of MOR stock can currently be purchased for approximately €93.30.
How big of a company is MorphoSys?
MorphoSys has a market capitalization of $2.95 billion and generates $87.19 million in revenue each year. MorphoSys employs 329 workers across the globe.
What is MorphoSys' official website?
How can I contact MorphoSys?
MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.
MarketBeat Community Rating for MorphoSys (ETR MOR)
MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
